A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback